REG - Destiny Pharma PLC - Publication of new microbiological data for XF-73

Destiny PharmaAnnouncement

17/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231017:nRSQ3005Qa&default-theme=true

RNS Number : 3005Q  Destiny Pharma PLC  17 October 2023

Destiny Pharma plc
("Destiny Pharma" or "the Company")

 

New publication shows XF-73 drug potent against 2,527 Staphylococcus isolates

Largest study of its kind to date demonstrates effectiveness of XF-73 against
all tested antibiotic resistant strains

 

Brighton, United Kingdom - 17 October 2023 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, today announces the publication of new microbiological data on
XF-73 (exeporfinium chloride), its leading antibacterial drug, in Frontiers in
Cellular and Infection Microbiology
(https://www.frontiersin.org/articles/10.3389/fcimb.2023.1264456/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Cellular_and_Infection_Microbiology&id=1264456)
.

 

The paper, 'Screening of the novel antimicrobial drug XF-73 against 2,527
Staphylococcus species clinical isolates', examined the efficacy of XF-73
against more than 2,500 Staphylococcus isolates with wide geographical and
clinical diversity. These isolates from 33 countries across Europe, North
America, South America, Asia and Africa, encompass 16 different staphylococcal
species, including resistant strains taken from patient infections such as
skin and soft tissue infections, respiratory tract infections and
hospital-acquired pneumonia.

 

The screening of XF-73 against this wide range of isolates yielded the
following landmark findings:

 

·    XF-73 effective against all 2,527 isolates tested

 

·    XF-73 effective against all tested antibiotic resistance mechanisms

 

·    XF-73 effective against 840 MRSA(1) clinical isolates from around the
world

 

·   XF-73 effective against S. epidermidis, S. saprophyticus, S.
haemolyticus, S.capitis, S. hominis and S. lugdunensis - all of high clinical
significance(2)

 

These critical findings support the urgency of XF-73 nasal's late-stage
development and need for its global regulatory approval.  XF‑73
demonstrates exceptionally broad potency across a huge range of Staphylococcus
isolates, including antibiotic resistant strains, with no resistance observed.
This study demonstrates XF-73's global effectiveness and reinforces the
significant commercial opportunity. Importantly it also demonstrates the
potential of XF-73 nasal to address the shortcomings of current standard of
care nasal antibiotics, which contribute to the global rise in Staphylococcus
aureus antibiotic resistance thereby limiting the effectiveness of current
infection reduction approaches.

 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma said: "This
peer-reviewed publication demonstrates that XF-73 has activity against all
global staphylococcal strains tested that were obtained from patients who had
infection from these bacteria.  This landmark data set will support the
approval process for this breakthrough drug in our lead indication for the
prevention of postsurgical staphylococcal infection."

 

Chris Tovey, CEO of Destiny Pharma, added: "The World Health Organisation has
declared antimicrobial resistance to be one of the top ten global public
health threats facing humanity. These new findings underscore the
transformative potential of XF-73 nasal not only to prevent post-surgical
infection of a vast range of staphylococcal strains but also, critically, to
be effective against all S. aureus tested antibiotic resistant strains. We
look forward to sharing further details on the importance of these findings at
our XF pipeline event later today."

 

References:

 

1.
https://www.doherty.edu.au/news-events/news/who-global-priority-pathogens-list-of-antibiotic-resistant-bacteria
(https://www.doherty.edu.au/news-events/news/who-global-priority-pathogens-list-of-antibiotic-resistant-bacteria)

 

2.    Michels, R., Last, K., Becker, S. L., and Papan, C. (2021). Update on
Coagulase-Negative Staphylococci-What the Clinician Should Know.
Microorganisms 9, 830. doi: 10.3390/microorganisms9040830

 

- END -

 

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

 

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZMMGLVKGFZM